Results 191 to 200 of about 30,114 (242)

Immunopathology of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. [PDF]

Int J Mol Sci
Lisowska KA, Wardowska A.
europepmc   +1 more source

Single-Cell RNA-Sequencing of Peripheral Blood Reveals Neutrophil Heterogeneity in Childhood ANCA-Associated Vasculitis. [PDF]

J Inflamm Res
Wei S, Tan L, Tang L, Xiong HY, Yang Q, Jiao J, Liu Z, Zhang G, Yang H, Li Q, Zhang A, Wang M.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Biologics for ANCA-Associated Vasculitis

Inflammation & Allergy-Drug Targets, 2014
The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a group of necrotizing vasculitides with a potential fatal outcome. Conventional therapy is based on the use of glucocorticoids (GCs) and cyclophosphamide (CYC), which is associated with severe toxic effects and is unable to control the disease activity in some refractory ...
Murgia G, FIRINU, DAVIDE, MANCONI, PAOLO EMILIO, DEL GIACCO, STEFANO   +3 more
openaire   +3 more sources

Pathophysiology of ANCA-associated Vasculitis

Advances in Anatomic Pathology, 2017
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is characterized as inflammation of small-sized to medium-sized blood vessels and encompasses several clinicopathologic entities including granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited ANCA-associated ...
Turki, Al-Hussain, Maged H, Hussein, Walter, Conca, Hadeel, Al Mana, Mohammed, Akhtar   +4 more
openaire   +2 more sources

Management of ANCA associated vasculitis

BMJ, 2020
ABSTRACTAnti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is a small to medium vessel vasculitis associated with excess morbidity and mortality. This review explores how management of AAV has evolved over the past two decades with pivotal randomized controlled trials shaping the management of induction and maintenance of remission.
Zachary S, Wallace, Eli M, Miloslavsky
openaire   +2 more sources

Rituximab in ANCA-Associated Vasculitis

Current Rheumatology Reports, 2017
The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV).A PubMed search was carried out to track down articles published between February 2006 and February 2016.
Romina I, Hassan, Angelo L, Gaffo
openaire   +2 more sources

ANCA-ASSOCIATED VASCULITIS

Acta Clinica Belgica, 2013
info:eu-repo/semantics ...
openaire   +3 more sources